Pregabalin Capsule
Product Images NDC 82804-949

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-949). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-943-30 (Image 01)

Pregabalin 25 mg capsules packaging label from Proficient Rx LP. The label indicates it contains 30 capsules, each with 25 mg pregabalin USP. The capsule is described as a white, hard-gelatin capsule printed with black ink: "SK+F" on the cap and "PG 25" on the body. The manufacturer is SK+F Eskayef Pharmaceuticals Limited, Bangladesh. Storage instructions and warnings are included.*

FDA Label Image

82804-944-30 (Image 02)

Label for Pregabalin 50 mg capsules, containing 30 capsules per package. The label indicates RX-only and a Schedule C-V classification. The medication is manufactured by SK+F ESKAYEF PHARMACEUTICALS LIMITED in Bangladesh and packaged by Proficient Rx LP in Thousand Oaks, CA. The label describes the capsule as white, hard-gelatin with black ink markings "SK+F" and "PG 50" with an ink band.*

FDA Label Image

82804-945-30 (Image 03)

Label for Pregabalin 75 mg capsules, containing 30 capsules. The label displays the National Drug Code (NDC) 82804-945-30 and indicates prescription-only status (C-V). It is packaged by Proficient Rx LP, Thousand Oaks, CA, and manufactured by SK+F Eskayef Pharmaceuticals Limited, Bangladesh. The label describes the capsules as orange/white hard gelatin with specific imprinting and instructs storage at 20°-25°C.*

FDA Label Image

82804-946-30 (Image 04)

Pregabalin 100 mg capsules label by Proficient Rx LP. The label states the quantity as 30 capsules, each containing 100 mg of pregabalin. It mentions the capsule is an orange, hard-gelatin capsule printed with black ink markings. The manufacturer is SK+F Eskayef Pharmaceuticals Limited located in Bangladesh. Storage instructions indicate to keep between 20°-25°C and out of reach of children. The label includes an NDC number and a controlled substance schedule C-V designation.*

FDA Label Image

82804-947-30 (Image 05)

Label for Pregabalin 150 mg oral capsules by Proficient Rx LP. The container holds 30 capsules. Each capsule contains 150 mg of pregabalin, USP. The label includes storage instructions (20°-25°C), manufacturer details (SK+F ESKAYEF Pharmaceuticals Limited, Bangladesh), and identifies the drug as Schedule V (C-V) prescription only. The capsules are described as white hard gelatin with black ink markings.*

FDA Label Image

82804-948-30 (Image 06)

Label for Pregabalin 200 mg capsules, prescription drug packaged by Proficient Rx LP. The label indicates 30 capsules per container. It includes dosage form, strength, manufacturer SK+F Eskayef Pharmaceuticals Limited in Bangladesh, storage temperature, and caution to keep out of reach of children. The capsule is described as light orange hard gelatin with specific black print markings.*

FDA Label Image

82804-949-30 (Image 07)

Label for Pregabalin 225 mg capsules by Proficient Rx LP showing a package quantity of 30 capsules. The label includes dosage form as oral capsules, and notes the capsule is light orange/white hard gelatin with specific black ink markings. Manufacturer is SK+F Eskayef Pharmaceuticals Limited, Bangladesh. The label includes NDC 82804-949-30 and indicates the drug is Schedule C-V and prescription only.*

FDA Label Image

82804-950-30 (Image 08)

Label for Pregabalin 300 mg capsules by Proficient Rx LP, showing a package of 30 capsules. The label indicates the active ingredient as 300 mg pregabalin USP per capsule. The capsules are described as orange and white hard gelatin with black print 'SK+F' on the cap and 'PG 300' on the body. Manufacturer is SK+F Eskayef Pharmaceuticals Limited, Bangladesh.*

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of Pregabalin, showing its molecular layout including an amino (NH2) group and carboxylic acid (CO2H) group attached to a branched carbon chain.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin doses of 25 mg, 100 mg, and 200 mg three times a day with placebo. The vertical axis shows the percent of patients improved, and the horizontal axis indicates the percent improvement in pain.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph showing the percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. The graph compares Pregabalin 100 mg three times a day to placebo, with Pregabalin showing a higher percentage of patients improved across various levels of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph depicting percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. The graph compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, against a placebo. Each dosage is represented by distinct line styles showing varying levels of patient improvement.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating patient response rates at different pain improvement thresholds.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups. The graph compares patient improvement rates over a range of pain reduction percentages, indicating higher improvement percentages for Pregabalin doses compared to placebo.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart comparing responder rates (%) from two clinical studies, Study E1 and Study E3, for Pregabalin at various dosages versus placebo. The vertical axis shows responder rates from 0% to 60%. The horizontal axis lists placebo and Pregabalin doses ranging from 50 mg/day to 600 mg/day with dosing frequency (BID, TID) indicated.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph depicting seizure reduction as median percent change from baseline on the y-axis and dose in mg/day on the x-axis for Pregabalin. It shows four study groups: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID, with statistically significant p-values noted for various dose levels compared to placebo dose 0.*

FDA Label Image

Figure 8 (Pregabalin 09)

A bar chart showing responder rates (%) for three groups: placebo (22.6% responder rate, n=93), 2.5 mg/kg/day dose (29.1% responder rate, n=103), and 10 mg/kg/day dose (40.6% responder rate, n=96). The y-axis indicates responder rate percentages up to 60%.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph depicting percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The figure compares four groups: Pregabalin 600 mg daily dose, 450 mg daily dose, 300 mg daily dose, and placebo, showing how patient improvement varies across these dosages.*

FDA Label Image

Figure 10 (Pregabalin 11)

A Kaplan-Meier survival curve graph showing estimated percentage of subjects without LTR over 180 days. Two lines compare Pregabalin (solid line) and Placebo (dashed line), with the Pregabalin group consistently having a higher estimated percentage of subjects without LTR throughout the period.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line graph comparing the percentage of subjects improved from baseline to week 12 based on the percent improved scale, for Pregabalin capsules versus placebo. The x-axis represents percent improved from 0 to 100, while the y-axis shows the percent of subjects improved. Two lines show outcomes, with Pregabalin consistently higher than placebo across improvement percentages.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line graph comparing the percent of subjects improved from baseline to week 16 in a study of Pregabalin versus Placebo. The x-axis shows percent improved from 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100%. Two lines represent Pregabalin (solid) and Placebo (dotted), demonstrating greater improvement with Pregabalin over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.